Boston Heart Diagnostics

Unlock Deeper Insights into Heart Health with Boston Heart Diagnostics

Boston Heart Diagnostics is a pioneering leader in cardiovascular health, offering a wide array of innovative and personalized diagnostic tests designed to deliver comprehensive insights into heart health.

Advanced Diagnostics for Better Heart Health

By leveraging cutting-edge laboratory technologies, Boston Heart Diagnostics provides critical information to support informed decision-making for both patients and healthcare providers. Their testing goes beyond traditional lipid panels to include:

Genetic markers
Inflammation indicators
Novel biomarkers

This holistic approach delivers a complete picture of an individual’s cardiovascular health.

Personalized Care Through Innovation

Boston Heart Diagnostics empowers patients and providers with the tools needed for early detection, effective management, and the development of personalized treatment plans. Their advanced methods focus on improving outcomes and fostering healthier lives through targeted care.

A Trusted Partner in Cardiovascular Diagnostics

With a strong commitment to excellence and a patient-centric approach, Boston Heart Diagnostics stands at the forefront of cardiovascular diagnostics. Their innovative testing solutions make them an invaluable partner for anyone seeking to understand and improve their heart health.

Take control of your heart health today with Boston Heart Diagnostics — redefining cardiovascular care for better outcomes.

Popular test panels by Boston Heart Diagnostics:

Boston Heart Cholesterol Balance Test

The Boston Heart Cholesterol Balance® test directly measures key cholesterol production and absorption markers associated with circulating total cholesterol (TC) by analyzing lathosterol, desmosterol, beta-sitosterol, campesterol, and cholestanol

Learn more

Boston Heart HDL Map Test

Plasma

OVERVIEW OF THE HDL MAP Standard HDL-C tests only measure the total amount of HDL-C contained by all HDL particles. Boston Heart’s exclusive HDL Map test measures the amount of apoA-I in the five most significant subpopulations, resulting in